Providing a VOICE for Kansas' MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1994
Meetings & Education
State Society Education Series
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
Patient Advocacy Organizations
National Professional Organizations
KaSCO Corporate Members
Become a Supporter
Industry News Archive
FDA Approves Pembrolizumab for Treatment of PMBCL
On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.
Read the FDA press release here.
Tweets by KS_Oncology